- Home
- CADL vs RCS Comparison
CADL vs RCS Comparison
Compare CADL & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CADL | RCS |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 290.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CADL | RCS |
|---|---|---|
| Price | $5.67 | $5.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.43 | N/A |
| AVG Volume (30 Days) | ★ 976.9K | 141.1K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $4.51 |
| 52 Week High | $13.68 | $6.31 |
Technical Indicators
Market Signals| Indicator | CADL | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 26.12 |
| Support Level | $5.45 | $6.14 |
| Resistance Level | $6.14 | $6.35 |
| Average True Range (ATR) | 0.40 | 0.18 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 16.73 | 0.93 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.